MDXH Overview

MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.

Wall Street analysts forecast MDXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDXH is7.67 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

MDxHealth SA revenue for the last quarter amounts to NaN USD, decreased

MDxHealth SA. EPS for the last quarter amounts to USD, decreased

MDxHealth SA (MDXH) has 312 emplpoyees as of May 15 2026.

Today MDXH has the market capitalization of 100.16M USD.